Stryker Corporation vs Atlassian Corporation PLC — how do they compare? Stryker Corporation trades at $276.3 (market cap $106.03B), while Atlassian Corporation PLC trades at $178.15 (market cap $44.66B). The key difference: Stryker Corporation is far larger — about 2.4× Atlassian Corporation PLC's market cap, and Stryker Corporation pays a 1.27% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| SYK | TEAM | |
|---|---|---|
Market Cap | $106.03B | $44.66B |
Sector | Technology | Technology |
52-Week High | $388.79 | $194.68 |
52-Week Low | $275.39 | $57.15 |
Enterprise Value | $117.50B | $44.65B |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Atlassian (TEAM) trades at $176.42, down 6.94% on the day, despite strong recent performance with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with support at $173 and resistance at $182. Revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable with a -0.82% net income margin. Analyst consensus is strongly bullish with 30 buy ratings and a $179.81 price target, while recent news highlights AI integration driving cloud growth.
TEAM presents a growth-oriented investment with significant upside potential from AI adoption and market expansion, but carries risks from persistent losses, premium valuation (P/S 6.98), and insider selling. The path to profitability remains key, with projected net losses narrowing to -$54M in 2026. Investors should weigh strong analyst support against high execution demands in a competitive SaaS landscape.
Trailing returns across standard periods
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →